BioInvent International AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BOVNF research report →
About the company
BioInvent International AB (publ) is a clinical-stage biotechnology company primarily focused on identifying, exploring, and engineering immunomodulatory antibodies to combat various forms of cancer. The company's activities extend globally, reaching markets in Sweden, across Europe, the United States, Japan, and other international regions. Its leading investigational compound is BI-1206, which is being developed to address both non-Hodgkin lymphoma and a range of solid tumors.
- CEO
- Martin Welschof
- IPO
- 2013
- Employees
- 114
- HQ
- Lund, SE
Price Chart
- Market Cap
- $216.40M
- P/E
- -5.02
- P/S
- 7.72
- P/B
- 3.83
- EV/EBITDA
- -4.08
- Div Yield
- 0.00%
- Gross Margin
- 98.48%
- Op Margin
- -161.05%
- Net Margin
- -153.98%
- ROE
- -53.88%
- ROIC
- -78.78%
- Revenue
- $225.93M · 405.59%
- Net Income
- $-332,023,010 · 22.67%
- EPS
- $-5.07 · 22.36%
- Op Income
- $-350,509,523
- FCF YoY
- 34.86%
- 52W High
- $4.70
- 52W Low
- $3.29
- 50D MA
- $3.29
- 200D MA
- $3.29
- Beta
- 0.00
- Avg Volume
- 588.384
Get TickerSpark's AI analysis on BOVNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BOVNF coverage
Recent articles, reports, and earnings notes.
No research on BOVNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BOVNF report →Similar companies
Peers in the same neighborhood.